Protagonist Therapeutics Return on Investment 2015-2022 | PTGX

Current and historical return on investment (ROI) values for Protagonist Therapeutics (PTGX) over the last 10 years.
Protagonist Therapeutics ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2022-03-31 $-0.12B inf%
2021-12-31 $-0.13B inf%
2021-09-30 $-0.11B inf%
2021-06-30 $-0.08B inf%
2021-03-31 $-0.07B inf%
2020-12-31 $-0.07B -361.11%
2020-09-30 $-0.06B -155.56%
2020-06-30 $-0.07B -177.78%
2020-03-31 $-0.09B $0.07B -209.88%
2019-12-31 $-0.08B $0.09B -355.56%
2019-09-30 $-0.08B inf%
2019-06-30 $-0.07B inf%
2019-03-31 $-0.05B inf%
2018-12-31 $-0.04B inf%
2018-09-30 $-0.03B inf%
2018-06-30 $-0.03B inf%
2018-03-31 $-0.03B inf%
2017-12-31 $-0.04B inf%
2017-09-30 $-0.05B inf%
2017-06-30 $-0.05B inf%
2017-03-31 $-0.04B inf%
2016-12-31 $-0.03B inf%
2016-06-30 $-0.02B inf%
2016-03-31 $-0.01B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.385B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00